{"id":7268,"date":"2024-03-27T09:38:41","date_gmt":"2024-03-27T01:38:41","guid":{"rendered":"https:\/\/flcube.com\/?p=7268"},"modified":"2024-10-17T09:41:23","modified_gmt":"2024-10-17T01:41:23","slug":"lees-pharmaceutical-holdings-ltd-reports-2023-financials-with-focus-shift-to-patented-and-generic-drugs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=7268","title":{"rendered":"Lee\u2019s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs"},"content":{"rendered":"\n

Lee\u2019s Pharmaceutical Holdings Ltd (HKG: 0950<\/a>), a leading pharmaceutical company based in China, has released its financial report for 2023, showing revenues of HKD 1.053 billion (USD 135 million), marking a 14.6% decrease year-on-year (YOY). The gross profit for the period was HKD 551 million (USD 70.4 million), a 28.5% YOY decline. The company’s investment in research and development reached HKD 220 million (USD 28.1 million), down by 37.5% YOY. Sales and distribution expenses also saw a reduction, amounting to HKD 304 million (USD 38.9 million), a 12.2% decrease YOY.<\/p>\n\n\n\n

Historically, in-licensed products have dominated the company’s sales. However, starting from 2023, Lee\u2019s Pharma has shifted its focus towards patented and generic drugs. During the reported period, these two categories generated HKD 467 million and HKD 586 million in revenues, respectively, accounting for 44.4% and 55.6% of total revenues. This is a shift from the 59.5% and 40.5% share they held in 2022.<\/p>\n\n\n\n

Despite the overall decline, certain products have seen significant sales growth. Bredinin (mizoribine), a renal transplant rejection inhibiting agent, Ferplex (iron proteinsuccinylate), an iron supplement, treprostinil for pulmonary hypertension, and trazodone, an antidepressant, reported growth rates of 18.9%, 11.3%, 13.9%, and 219.3%, respectively.<\/p>\n\n\n\n

In 2022, Lee\u2019s Pharma began participating in the national volume-based procurement (VBP) tender rounds. Fondaparinux and nadroparin, both part of the heparin VBP round, recorded sales of HKD 22.1 million and HKD 82.7 million, respectively, accounting for 10.0% of total revenues.<\/p>\n\n\n\n

In 2023, Lee\u2019s Pharma achieved three new marketing approvals: apremilast, a PDE4 inhibitor for the treatment of psoriasis; NOmax, a vasodilator indicated for the treatment of full-term infants with hypoxic respiratory failure accompanied by pulmonary hypertension and premature infants over 34 weeks old; and Adasuve (loxapine) for acute treatment of adult schizophrenia or bipolar disorder related agitation.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Lee\u2019s Pharmaceutical Holdings Ltd (HKG: 0950), a leading pharmaceutical company based in China, has released…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,941,165],"class_list":["post-7268","post","type-post","status-publish","format-standard","hentry","category-company","tag-finanical-reports","tag-hkg-0950","tag-lees-pharmaceutical"],"yoast_head":"\nLee\u2019s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lee\u2019s Pharmaceutical Holdings Ltd (HKG: 0950), a leading pharmaceutical company based in China, has released its financial report for 2023, showing revenues of HKD 1.053 billion (USD 135 million), marking a 14.6% decrease year-on-year (YOY). The gross profit for the period was HKD 551 million (USD 70.4 million), a 28.5% YOY decline. The company's investment in research and development reached HKD 220 million (USD 28.1 million), down by 37.5% YOY. Sales and distribution expenses also saw a reduction, amounting to HKD 304 million (USD 38.9 million), a 12.2% decrease YOY.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=7268\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lee\u2019s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=7268\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-27T01:38:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-17T01:41:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7268#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7268\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lee\u2019s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs\",\"datePublished\":\"2024-03-27T01:38:41+00:00\",\"dateModified\":\"2024-10-17T01:41:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7268\"},\"wordCount\":286,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finanical Reports\",\"HKG: 0950\",\"Lee's Pharmaceutical\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=7268#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7268\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=7268\",\"name\":\"Lee\u2019s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-03-27T01:38:41+00:00\",\"dateModified\":\"2024-10-17T01:41:23+00:00\",\"description\":\"Lee\u2019s Pharmaceutical Holdings Ltd (HKG: 0950), a leading pharmaceutical company based in China, has released its financial report for 2023, showing revenues of HKD 1.053 billion (USD 135 million), marking a 14.6% decrease year-on-year (YOY). The gross profit for the period was HKD 551 million (USD 70.4 million), a 28.5% YOY decline. The company's investment in research and development reached HKD 220 million (USD 28.1 million), down by 37.5% YOY. Sales and distribution expenses also saw a reduction, amounting to HKD 304 million (USD 38.9 million), a 12.2% decrease YOY.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7268#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=7268\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7268#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lee\u2019s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lee\u2019s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs - Insight, China's Pharmaceutical Industry","description":"Lee\u2019s Pharmaceutical Holdings Ltd (HKG: 0950), a leading pharmaceutical company based in China, has released its financial report for 2023, showing revenues of HKD 1.053 billion (USD 135 million), marking a 14.6% decrease year-on-year (YOY). The gross profit for the period was HKD 551 million (USD 70.4 million), a 28.5% YOY decline. The company's investment in research and development reached HKD 220 million (USD 28.1 million), down by 37.5% YOY. Sales and distribution expenses also saw a reduction, amounting to HKD 304 million (USD 38.9 million), a 12.2% decrease YOY.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=7268","og_locale":"en_US","og_type":"article","og_title":"Lee\u2019s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=7268","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-03-27T01:38:41+00:00","article_modified_time":"2024-10-17T01:41:23+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=7268#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=7268"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lee\u2019s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs","datePublished":"2024-03-27T01:38:41+00:00","dateModified":"2024-10-17T01:41:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=7268"},"wordCount":286,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finanical Reports","HKG: 0950","Lee's Pharmaceutical"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=7268#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=7268","url":"https:\/\/flcube.com\/?p=7268","name":"Lee\u2019s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-03-27T01:38:41+00:00","dateModified":"2024-10-17T01:41:23+00:00","description":"Lee\u2019s Pharmaceutical Holdings Ltd (HKG: 0950), a leading pharmaceutical company based in China, has released its financial report for 2023, showing revenues of HKD 1.053 billion (USD 135 million), marking a 14.6% decrease year-on-year (YOY). The gross profit for the period was HKD 551 million (USD 70.4 million), a 28.5% YOY decline. The company's investment in research and development reached HKD 220 million (USD 28.1 million), down by 37.5% YOY. Sales and distribution expenses also saw a reduction, amounting to HKD 304 million (USD 38.9 million), a 12.2% decrease YOY.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=7268#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=7268"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=7268#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lee\u2019s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/7268","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7268"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/7268\/revisions"}],"predecessor-version":[{"id":7269,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/7268\/revisions\/7269"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7268"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7268"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7268"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}